Prostate cancer rates vary substantially by race, ethnicity, and geography. These disparities
can be explained by variation in access to screening and treatment, variation in exposure to …

Since the introduction of serum prostate-specific antigen (PSA) screening 25 years ago,
prostate cancer diagnosis and management have been guided by this biomarker. Yet, PSA …

Genome-wide DNA sequencing was used to decrypt the phylogeny of multiple samples from
distinct areas of cancer and morphologically normal tissue taken from the prostates of three …

Background Understanding the heterogeneous genotypes and phenotypes of prostate
cancer is fundamental to improving the way we treat this disease. As yet, there are no …

Purpose Studies indicate that castration-resistant prostate cancer (CRPC) remains driven by
ligand-dependent androgen receptor (AR) signaling. To evaluate this, a trial of abiraterone …

Rare circulating tumor cells (CTCs) are present in the blood of patients with metastatic
epithelial cancers but have been difficult to measure routinely. We report a quantitative …

The discovery of recurrent gene fusions in a majority of prostate cancers has important
clinical and biological implications in the study of common epithelial tumours. Gene fusion …

Background: Whether the genomic rearrangement transmembrane protease, serine 2
(TMPRSS2): v-ets erythroblastosis virus E26 oncogene homolog (ERG) has prognostic …

Hormone-driven expression of the ERG oncogene after fusion with TMPRSS2 occurs in 30%
to 70% of therapy-naive prostate cancers. Its relevance in castration-resistant prostate …

The TMPRSS2-ERG fusion, present in approximately 50% of prostate cancers, is less
common in prostatic intraepithelial neoplasia (PIN), raising questions about whether …